Trial Profile

A Phase 2 Multi-arm, Open Label Study to Assess the Safety and Efficacy of EP0057 in Combination With Olaparib in Defined Populations of Patients With Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 13 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EP-0057 (Primary) ; Olaparib (Primary)
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Small cell lung cancer
Focus Therapeutic Use
Sponsors Ellipses Pharma

09 Jun 2023 Status changed from not yet recruiting to withdrawn prior to enrolment. Reason the study was stopped: Futility analysis decision to terminate EP0057 compound and all Ellipses sponsored studies involving EP0057.
01 Nov 2022 Planned initiation date changed from 1 Jul 2022 to 1 Apr 2023.
14 Jun 2022 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com